OBJECTIVES: The objective of the study was to estimate the CoD in CRVO, in Turkish setting. METHODS: An expert panel was held by participation of five ophthalmologists to discuss the disease management in CRVO. Physicians reviewed the literature, discussed the local clinical practices and all cost components; pharmaceuticals, treatment administration, monitoring and adverse events. Two different treatment options (ranibizumab and dexamethasone) were studied. September-2014 local prices for medications and procedures were used as sources. September-2014 EUR currency rate (2.8671TL/EUR) was used. RESULTS: The frequency of treatments in a year were assumed as 8.8 and 2.0 and the numbers of outpatient visits in a year were accepted as 9 and 7 for ranibizumab and dexamethasone, respectively. Common adverse events were taken into account. The cost of cataract was accepted as equal to the cost of cataract removal operation which is 143EUR and the cost of retinal detachment was accepted as the average cost of surgical treatments as 368EUR. It was assumed that surgical treatment (trabeculectomy, Seton operation or cyclophotocoagulation) was applied in 2% of increased ocular pressure (IOP) patients (average cost 183EUR/operation). Pharmacologic treatment was assumed to be applied in 98% of the IOP patients (4EUR/patient). Thus, overall cost of IOP was calculated as 7EUR. The total CoD was calculated as 3,823EUR per patients treated with ranibizumab, where the cost excluding pharmaceutical was determined as 138EUR. The CoD in patients treated with dexamethasone was estimated as 1,195EUR which is lower when compared to CoD in patients treated with ranibizumab. Total cost excluding pharmaceutical was calculated 240EUR for dexamethasone. CONCLUSIONS: In CRVO, the cost of treatment formed the major part of the total CoD when compared to monitoring, administration and adverse event costs.